An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Micek, Scott ^a   Johnson, Michael T ^b   Reichley, Richard ^c   Kollef, Marin H ^d  

^a BARNES JEWISH HOSPITAL   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c BJC HEALTHCARE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Hospital costs; Length of stay; Outcomes; Severe sepsis

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CIPROFLOXACIN; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; BLOOD CULTURE; COHORT ANALYSIS; DRUG EXPOSURE; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE SEPSIS; HOSPITAL COST; HUMAN; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; MORTALITY; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; RISK FACTOR; ADOLESCENT; AGED; DRUG UTILIZATION; ECONOMICS; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; SEPSIS; STATISTICS; TEACHING HOSPITAL; URBAN POPULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COHORT STUDIES; DRUG UTILIZATION; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITAL COSTS; HOSPITALS, TEACHING; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEPSIS; URBAN POPULATION; YOUNG ADULT;

EID: 84863406826     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-56     Document Type: Article

References (25)

1. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008, 6:751-763. 10.1586/14787210.6.5.751, 18847410.
2. Miyakis S, Pefanis A, Tsakris A. The challenges of antimicrobial resistance in Greece. Clin Infect Dis 2011, 53:177-184. 10.1093/cid/cir323, 21690626.
3. Shorr A, Micek ST, Kollef MH. Inappropriate therapy for methicillin-resistant Staphylococcus aureu: resource utilization and cost implications. Crit Care Med 2008, 36:2335-2340. 10.1097/CCM.0b013e31818103ea, 18596624.
4. Zilberberg MD, Kollef MH, Arnold H, Labelle A, Micek ST, Kothari S, Shorr AF. Inappropriate empiric antifungal therapy for Candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 2010, 10:150. 10.1186/1471-2334-10-150, 2890008, 20525301.
5. Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH. Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med 2011, 39:46-51. 10.1097/CCM.0b013e3181fa41a7, 20890186.
6. Shorr AF, Micek ST, Jackson WL. Kollef MH: Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs?. Crit Care Med 2007, 35:1257-1262. 10.1097/01.CCM.0000261886.65063.CC, 17414080.
7. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474. 10.1378/chest.115.2.462, 10027448.
8. Dhainaut JF, Laterre PF, LaRosa SP, Levy H, Garber GE, Heiselman D, Kinasewitz GT, Light RB, Morris P, Schein R, Sollet JP, Bates BM, Utterback BG, Maki D. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit Care Med 2003, 31:2291-2301. 10.1097/01.CCM.0000085089.88077.AF, 14501959.
9. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003, 31:2742-2751. 10.1097/01.CCM.0000098031.24329.10, 14668610.
10. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003, 115:529-535. 10.1016/j.amjmed.2003.07.005, 14599631.
11. Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Pérez XL, Sirvent JM. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009, 180:861-866. 10.1164/rccm.200812-1912OC, 19696442.
12. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century- a clinical super-challenge. N Engl J Med 2009, 360:439-443. 10.1056/NEJMp0804651, 19179312.
13. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12. 10.1086/595011, 19035777.
14. Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis 2008, 47:S3-S13. 10.1086/590061, 18713047.
15. Barochia AV, Cui X, Vitberg D, Suffredini AF, O'Grady NP, Banks SM, Minneci P, Kern SJ, Danner RL, Natanson C, Eichacker PQ. Bundled care for septic shock: an analysis of clinical trials. Crit Care Med 2010, 38:668-678. 10.1097/CCM.0b013e3181cb0ddf, 20029343.
16. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327. 10.1097/01.CCM.0000298158.12101.41, 18158437.
17. Johnson MT, Reichley R, Hoppe-Bauer J, Dunne WM, Micek S, Kollef M. Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis. Crit Care Med 2011, 39:1859-1865. 10.1097/CCM.0b013e31821b85f4, 21499086.
18. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
19. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002, 11445675.
20. National Committee for Clinical Laboratory Standards Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement. M100-S12. 2002, National Committee for Clinical Laboratory Standards, Wayne, PA, National Committee for Clinical Laboratory Standards.
21. Clinical Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement. M100-S17. 2007, Clinical Laboratory Standards Institute, Wayne, PA, Clinical Laboratory Standards Institute.
22. Webster DP, Young BC, Morton R, Collyer D, Batchelor B, Turton JF, Maharjan S, Livermore DM, Bejon P, Cookson BD, Bowler IC. Impact of a clonal outbreak of extended-spectrum {beta}-lactamase-producing Klebsiella pneumonia in the development and evolution of bloodstream infections by K. pneumonia and Escherichia col an 11 year experience in Oxfordshire, UK. J Antimicrob Chemother 2011, 66:2126-2135. 10.1093/jac/dkr246, 21693458.
23. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M. Imipenem resistance in Pseudomonas aeruginos: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol 2010, 31:47-53. 10.1086/649021, 19951202.
24. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginos bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005, 49:1306-1311. 10.1128/AAC.49.4.1306-1311.2005, 1068618, 15793102.
25. Johnson SJ, Ernst EJ, Moores KG. Is double coverage of gram-negative organisms necessary?. Am J Health Syst Pharm 2011, 68:119-124. 10.2146/ajhp090360, 21200057.